3 completed, 2 recruiting, 2 unknown, 1 active not recruiting. 10 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 10 | Completed 3, Recruiting 2, Unknown 2, Active not recruiting 1, Not yet recruiting 1, Terminated 1 |
| Phase 2 | 1 | Completed 1 |
Follow Hematologic Malignancy: new trials by email Literature Review of Hematologic Malignancy trials Research Report on Hematologic Malignancy
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Comparing the Efficacy of Different Durations of Maribavir Treatment Regimens in Allo-HSCT Maribavir - Hematologic Malignancy | Phase 3 | Recruiting | Ruijin Hospital | 218 | 2026-02-28 | 2026-04-06 |
| An Extension Study for Patients Previously Enrolled in Studies With Pelabresib Pelabresib, Ruxolitinib - Hematologic Malignancy, Solid Tumor | Phase 3 | Recruiting | Novartis Pharmaceuticals | 50 | 2024-08-13 | 2026-11-12 |
| CMV-specific T Cell Immunity Test Indicated Prophylaxis of Letermovir After All-HSCT Letermovir - Hematologic Malignancy | Phase 3 | Active not recruiting | Ruijin Hospital | 250 | 2024-07-01 | 2025-12-15 |
| Early Neutropenic Fever De-escalation of Antibiotics Study Cessation of antibiotics - Hematologic Malignancy, Febrile Neutropenia | Phase 3 | Not yet recruiting | Brigham and Women's Hospital | 260 | 2024-03-01 | 2024-02-26 |
| ATG Plus Low-dose PT-Cy for GVHD Prevention Cyclophosphamid, ATG - Hematologic Malignancy | Phase 3 | Terminated | Peking University People's Hospital | 66 | 2023-11-01 | 2025-06-03 |
| Impact of Aminoglycosides-based Antibiotics Combination and Protective Isolation on Outcomes in Critically-ill Neutropenic Patients With Sepsis: (Combination-Lock01) Aminoglycosides intervention, Lack of protective isolation intervention, No systematic aminoglycosides intervention - standard arm - Sepsis, Septic Shock | Phase 3 | Unknown | Assistance Publique - Hôpitaux de Paris | 340 | 2022-09-01 | 2022-07-05 |
| Comparison of PT-Cy at a Dose of 25 mg/kg/Day and PT-Cy at a Dose of 50 mg/kg/Day in GVHD Prophylaxis Post-transplantation Cyclophosphamide at dose 25 mg/kg/day, Post-transplantation Cyclophosphamide at dose 50 mg/kg/day - Graft Versus Host Disease, Hematologic Malignancy | Phase 3 | Unknown | National Research Center for Hematology, Russia | 100 | 2022-01-01 | 2022-01-11 |
| Expressive Helping for Stem Cell Transplant Patients Expressive Helping, Factual Writing - Stem Cell Transplantation, Hematologic Malignancy | Phase 3 | Completed | Northwestern University | 405 | 2019-03-06 | 2023-05-06 |
| Efficacy of Prophylactic Low Level Laser Therapy (LLLT) Performed by Nurses for Decreasing Severity of Oral Mucositis During Hematopoietic Stem Cell (HSC) Transplantation Laser treatment, Placebo - Hematologic Malignancy | Phase 3 | Completed | Institut de Cancérologie de la Loire | 234 | 2016-06-27 | 2020-01-29 |
| Mindfulness Meditation in Bone Marrow Transplantation Mindfulness training, Nurse education - Hematologic Malignancy, Bone Marrow Transplantation | Phase 2 / Phase 3 | Completed | Emory University | 241 | 2005-04-01 | 2013-11-28 |
Hematologic Neoplasms (10) · Febrile Neutropenia (1) · Graft vs Host Disease (1) · Mucositis (1) · Neoplasms (1) · Sepsis (1) · Shock, Septic (1)
Hematologic Diseases (10) · Hemic and Lymphatic Diseases (10) · Neoplasms by Site (10) · Neoplasms (9) · Agranulocytosis (1) · Cytopenia (1) · Digestive System Diseases (1) · Gastroenteritis (1) · Gastrointestinal Diseases (1) · Immune System Diseases (1) · Infections (1) · Inflammation (1) · Leukocyte Disorders (1) · Leukopenia (1) · Mouth Diseases (1)
Cyclophosphamide (2) · CPI-0610 (1) · Laser Therapy (1) · letermovir (1) · maribavir (1) · ruxolitinib (1) · trihexyltetradecylphosphonium chloride (1)
Ruijin Hospital (2) · Assistance Publique - Hôpitaux de Paris (1) · Brigham and Women's Hospital (1) · Emory University (1) · Institut de Cancérologie de la Loire (1) · National Research Center for Hematology, Russia (1) · Northwestern University (1) · Novartis Pharmaceuticals (1) · Peking University People's Hospital (1)
China (3) · United States (3) · Belgium (1) · France (1) · Italy (1) · Netherlands (1) · United Kingdom (1)
Elena Parovichnikova, MD, D.Sc (1) · Lindsey R Baden, MD (1) · Susan Bauer-Wu, PhD (1)
2023 (1), R01CA223963 (1)